Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 (68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Literature DB >> 24899958

(68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Dinesh Shetty¹, Yun-Sang Lee¹, Jae Min Jeong¹.

Abstract

(68)Ga is a promising emerging radionuclide for positron emission tomography (PET). It is produced using a (68)Ge/(68)Ga-generator, and thus, would enable the cyclotron-independent distribution of PET. However, new (68)Ga-labeled radiopharmaceuticals that can replace (18)F-labeled agents like [(18)F]fluorodeoxyglucose (FDG) are needed. Most of the (68)Ga-labeled derivatives currently used are peptide agents, but the developments of other agents, such as amino acid derivatives, nitroimidazole derivatives, and glycosylated human serum albumin, are being actively pursued in many laboratories. Thus, appearance of new (68)Ga-labeled radiopharmaceuticals with high impact are expected in the near future. Here, we present an overview of (68)Ga-labeled agents in terms of their clinical significances and relevances to the management of certain tumors, and pertinent pre-clinical developments.

Entities: Chemical Disease Gene Species

Keywords: BAPEN; DOTA; Ga-68; Gallium-68; MSA; NOTA; PET; Peptide

Year: 2010 PMID： 24899958 PMCID： PMC4042918 DOI： 10.1007/s13139-010-0056-6

Source DB: PubMed Journal: Nucl Med Mol Imaging ISSN： 1869-3474

57 in total

Review 1. Synthesis of target-specific radiolabeled peptides for diagnostic imaging.

Authors: Jakub Fichna; Anna Janecka
Journal: Bioconjug Chem Date: 2003 Jan-Feb Impact factor: 4.774

2. A new myocardial imaging agent: synthesis, characterization, and biodistribution of gallium-68-BAT-TECH.

Authors: H F Kung; B L Liu; D Mankoff; M P Kung; J J Billings; L Francesconi; A Alavi
Journal: J Nucl Med Date: 1990-10 Impact factor: 10.057

3. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus.

Authors: Tatu J Mäkinen; Petteri Lankinen; Tiina Pöyhönen; Jari Jalava; Hannu T Aro; Anne Roivainen
Journal: Eur J Nucl Med Mol Imaging Date: 2005-07-09 Impact factor: 9.236

4. A new germanium-63/gallium-68 generator.

Authors: G J Ehrhardt; M J Welch
Journal: J Nucl Med Date: 1978-08 Impact factor: 10.057

5. Preparation of 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate. An improved method.

Authors: M Koizumi; K Endo; M Kunimatsu; H Sakahara; T Nakashima; Y Kawamura; Y Watanabe; Y Ohmomo; Y Arano; A Yokoyama
Journal: J Immunol Methods Date: 1987-11-23 Impact factor: 2.303

6. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

Authors: Michael Gabriel; Clemens Decristoforo; Dorota Kendler; Georg Dobrozemsky; Dirk Heute; Christian Uprimny; Peter Kovacs; Elisabeth Von Guggenberg; Reto Bale; Irene J Virgolini
Journal: J Nucl Med Date: 2007-04 Impact factor: 10.057

7. Structure-distribution relationships for metal-labeled myocardial imaging agents: comparison of a series of cationic gallium (III) complexes with hexadentate bis(salicylaldimine) ligands.

Authors: B W Tsang; C J Mathias; P E Fanwick; M A Green
Journal: J Med Chem Date: 1994-12-09 Impact factor: 7.446

8. 68Ga-labeled oligonucleotides for in vivo imaging with PET.

Authors: Anne Roivainen; Tuula Tolvanen; Satu Salomäki; Gabor Lendvai; Irina Velikyan; Petri Numminen; Maria Välilä; Hannu Sipilä; Mats Bergström; Pirkko Härkönen; Harri Lönnberg; Bengt Långström
Journal: J Nucl Med Date: 2004-02 Impact factor: 10.057

9. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors.

Authors: Giuseppina Sabatino; Marco Chinol; Giovanni Paganelli; Stefano Papi; Mario Chelli; Giuseppe Leone; Anna Maria Papini; Angelo De Luca; Mauro Ginanneschi
Journal: J Med Chem Date: 2003-07-03 Impact factor: 7.446

10. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Authors: I Buchmann; M Henze; S Engelbrecht; M Eisenhut; A Runz; M Schäfer; T Schilling; S Haufe; T Herrmann; U Haberkorn
Journal: Eur J Nucl Med Mol Imaging Date: 2007-05-23 Impact factor: 9.236

10 in total

Review 1. An overview of the developments and potential applications of ⁶⁸Ga-labelled PET/CT hypoxia imaging.

Authors: Philippa L Bresser; Mariza Vorster; Mike M Sathekge
Journal: Ann Nucl Med Date: 2021-01-05 Impact factor: 2.668

Review 2. Radiotracers for positron emission tomography imaging.

Authors: Nic Gillings
Journal: MAGMA Date: 2012-12-16 Impact factor: 2.310

Review 3. The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.

Authors: Holis Abdul Holik; Faisal Maulana Ibrahim; Angela Alysia Elaine; Bernap Dwi Putra; Arifudin Achmad; Achmad Hussein Sundawa Kartamihardja
Journal: Molecules Date: 2022-05-10 Impact factor: 4.927

4. In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.

Authors: Choong Mo Kang; Sung-Min Kim; Hyun-Jung Koo; Min Su Yim; Kyung-Han Lee; Eun Kyoung Ryu; Yearn Seong Choe
Journal: Eur J Nucl Med Mol Imaging Date: 2012-10-25 Impact factor: 9.236

5. Radiosynthesis and bioevaluation of [68Ga]-labeled 5,10,15,20-tetra(4-methylpyridyl)-porphyrin for possible application as a PET radiotracer for tumor imaging.

Authors: Mohini Bhadwal; Tapas Das; Haladhar Dev Sarma; Sharmila Banerjee
Journal: Mol Imaging Biol Date: 2015-02 Impact factor: 3.488

10. Studies towards elucidating the potential of 5,10,15,20-tetrakis(p-carboxy-methyleneoxyphenyl)porphyrin as a theranostic agent for applications in PET and PDT.

Authors: Mohini Guleria; Chandan Kumar; Tapas Das; Jeyachitra Amirdhanayagam; Rohit Sharma; Haladhar D Sarma; Ashutosh Dash
Journal: Medchemcomm Date: 2018-02-12 Impact factor: 3.597

10 in total

(68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Review 1. Synthesis of target-specific radiolabeled peptides for diagnostic imaging.

2. A new myocardial imaging agent: synthesis, characterization, and biodistribution of gallium-68-BAT-TECH.

3. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus.

4. A new germanium-63/gallium-68 generator.

5. Preparation of 67Ga-labeled antibodies using deferoxamine as a bifunctional chelate. An improved method.

6. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.

7. Structure-distribution relationships for metal-labeled myocardial imaging agents: comparison of a series of cationic gallium (III) complexes with hexadentate bis(salicylaldimine) ligands.

8. 68Ga-labeled oligonucleotides for in vivo imaging with PET.

9. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors.

10. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.

Review 1. An overview of the developments and potential applications of ⁶⁸Ga-labelled PET/CT hypoxia imaging.

Review 2. Radiotracers for positron emission tomography imaging.

Review 3. The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.

4. In vivo characterization of 68Ga-NOTA-VEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models.

5. Radiosynthesis and bioevaluation of [68Ga]-labeled 5,10,15,20-tetra(4-methylpyridyl)-porphyrin for possible application as a PET radiotracer for tumor imaging.

6. Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT.

Review 7. Targets and probes for non-invasive imaging of β-cells.

8. Explicit measurement of multi-tracer arterial input function for PET imaging using blood sampling spectroscopy.

9. Synthesis and Characterization of Multifunctional Nanovesicles Composed of POPC Lipid Molecules for Nuclear Imaging.

10. Studies towards elucidating the potential of 5,10,15,20-tetrakis(p-carboxy-methyleneoxyphenyl)porphyrin as a theranostic agent for applications in PET and PDT.

Review 1. Synthesis of target-specific radiolabeled peptides for diagnostic imaging.

Review 1. An overview of the developments and potential applications of 68Ga-labelled PET/CT hypoxia imaging.

Review 2. Radiotracers for positron emission tomography imaging.

Review 3. The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.

Review 7. Targets and probes for non-invasive imaging of β-cells.

Review 1. An overview of the developments and potential applications of ⁶⁸Ga-labelled PET/CT hypoxia imaging.